• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Highlights Continued Commitment to Cardiovascular & Metabolic Healthcare Solutions with Late-Breaking Data at the First Fully Virtual American College of Cardiology Scientific Session
RARITAN, N.J., March 20, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that it will unveil late-breaking data from its leading cardiovascular and metabolism portfolio during the virtual American College of Cardiology’s 69th Annual Scientific Session together with the World Congress of Cardiology (ACC.20/WCC) on March 28-30, 2020. Notably, four late-breaking abstracts for XARELTO® (rivaroxaban) will be presented, including data from the Phase 3 VOYAGER PAD study in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization.Click to Tweet: Jan...
Source: Johnson and Johnson - March 20, 2020 Category: Pharmaceuticals Source Type: news

National Burden Estimates of healthy life lost in India, 2017: an analysis using direct mortality data and indirect disability data
Publication date: December 2019Source: The Lancet Global Health, Volume 7, Issue 12Author(s): Geetha R Menon, Lucky Singh, Palak Sharma, Priyanka Yadav, Shweta Sharma, Shrikant Kalaskar, Harpreet Singh, Srividya Adinarayanan, Vasna Joshua, Vaitheeswaran Kulothungan, Jeetendra Yadav, Leah K Watson, Shaza A Fadel, Wilson Suraweera, M Vishnu Vardhana Rao, R S Dhaliwal, Rehana Begum, Prabha Sati, Dean T Jamison, Prabhat JhaSummaryBackgroundMany countries, including India, seek locally constructed disease burden estimates comprising mortality and loss of health to aid priority setting for the prevention and treatment of disease...
Source: The Lancet Global Health - November 9, 2019 Category: International Medicine & Public Health Source Type: research

Needs of Internally Displaced Women and Children in Baghdad, Karbala, and Kirkuk, Iraq
Conclusions The vulnerability of this population is great, and the emotional trauma of multiple displacements, kidnapping and deaths from intentional violence is great. While some aid is reaching families, much more is needed. Though Iraq is a middle income country, reaching the IDPs in central Iraq will take much more in international assistance than is currently being received. Unfortunately, at this time of great need, assistance is being cut back throughout the region because of lack of funding.10 The local civil society organizations which have sprung up in many locations to assist IDPs, offer an avenue for targeting ...
Source: PLOS Currents Disasters - June 10, 2016 Category: Global & Universal Authors: Gilbert Burnham Source Type: research